Analyst Price Target News: Cadence, MGM Resorts, Sarepta – July 29th, 2025

By: Matthew Otto

Sarepta Therapeutics Gains Regulatory Clearance to Resume Partial U.S. Distribution of Elevidys

Sarepta Therapeutics has resumed U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD), for ambulatory patients, following a recommendation from the U.S. Food and Drug Administration (FDA). Elevidys was granted accelerated approval in June 2023 for use in boys aged 4 to 5 who can walk independently and have a confirmed DMD gene mutation. The therapy introduces a shortened version of the dystrophin gene, which is deficient in individuals with DMD.

Duchenne muscular dystrophy is a progressive genetic disorder affecting approximately 10,000 to 12,000 people in the United States, primarily males. An estimated 60% of these individuals are ambulatory and may fall within the currently approved treatment group, equivalent to around 6,000 to 7,000 patients. Shipments of Elevidys were paused earlier in 2025 following two deaths among non-ambulatory participants in clinical studies. The FDA’s latest guidance followed a separate investigation into the death of a patient in Brazil, which was found to be unrelated to the therapy.

Analyst Sami Corwin of William Blair noted that the FDA’s recommendation substantially reduces the likelihood of Elevidys being removed from the market and allows the company to meet short-term financial obligations, including payments to development partner Arrowhead Pharmaceuticals and requirements tied to debt facilities. However, Corwin also pointed out that recent events may lead to reduced confidence among physicians and caregivers. Shipments to non-ambulatory patients in the U.S. remain on hold, and Sarepta’s international partner Roche has continued its suspension of distribution in select markets outside the United States.

Analysts Adjust Ratings and Targets After FDA Update on Elevidys

Piper Sandler analyst Biren Amin maintained a Neutral rating while increasing the price target from $11 to $15.
Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating and raised the price target from $15 to $20.
Oppenheimer analyst Hartaj Singh upgraded from Perform to Outperform and the price target from $30 to $37.
JP Morgan analyst Anupam Rama upgraded from Underweight to Neutral and assigned a price target of $24.
Needham analyst Gil Blum reiterated an Underperform rating.

Which Analyst has the best track record to show on SRPT?

Analyst Mitchell Kapoor (HC WAINWRIGHT) currently has the highest performing score on SRPT with 8/14 (57.14%) price target fulfillment ratio. His price targets carry an average of $-7.46 (-42.73%) potential downside. Sarepta Therapeutics stock price reaches these price targets on average within 55 days.

Cadence Raises 2025 Outlook After Reporting Q2 Results and China Export Resumption

Cadence Design Systems reported second-quarter 2025 revenue of $1.275 billion, an increase of 20% from $1.061 billion in the same quarter last year. Diluted earnings per share were $0.59, down from $0.84 a year earlier, reflecting a $140.6 million legal settlement with the U.S. Department of Justice and the Bureau of Industry and Security. Excluding the settlement, diluted earnings per share increased to $1.65 from $1.28.

Operating margin for the quarter was 19%, compared to 27.7% in the prior-year period. When adjusted for one-time items, the margin rose to 42.8%, up from 40.1%. The company reported a total backlog of $6.4 billion, with $3.1 billion expected to be recognized as revenue within the next 12 months. Revenue from China represented 9% of total sales, down from 12% a year earlier, reflecting temporary export restrictions that were lifted earlier in July.

Cadence updated its full-year 2025 outlook in light of the export resumption. It now projects revenue in the range of $5.21 billion to $5.27 billion, up from the prior forecast of $5.15 billion to $5.23 billion. Adjusted earnings per share are expected to range from $6.85 to $6.95, compared to the earlier range of $6.73 to $6.83. Operating margin is forecast between 43.5% and 44.5%. Projected operating cash flow has also been increased to a range of $1.65 billion to $1.75 billion.

Cadence anticipates offsetting the settlement-related cash outflow through an estimated $140 million in reduced tax payments, due to recently enacted R&D expensing rules. Segment results included 16% year-over-year growth in core EDA tools, over 25% growth in IP products, and a 35% increase in system design and analysis revenues.

Analyst Ratings Diverge as Price Targets Move Higher Post-Q2

Stifel analyst Ruben Roy maintained a Buy rating while lifting the price target from $350 to $395.
Piper Sandler analyst Clarke Jeffries downgraded from Overweight to Neutral, yet raised the price target from $328 to $355.
Mizuho analyst Siti Panigrahi kept an Outperform rating and increased the price target from $360 to $375.
Needham analyst Charles Shi reiterated a Buy rating and boosted the price target from $325 to $390.

Which Analyst has the best track record to show on CDNS?

Analyst Blair Abernethy (ROSENBLATT) currently has the highest performing score on CDNS with 16/17 (94.12%) price target fulfillment ratio. His price targets carry an average of $-32.19 (-9.69%) potential downside. Cadence Design Systems stock price reaches these price targets on average within 35 days.

MGM Resorts Raises Full-Year Guidance Following First-Half Results from BetMGM

MGM Resorts International reported higher first-half 2025 results from its U.S. digital gaming joint venture, BetMGM, leading to an upward revision in its full-year projections. BetMGM, jointly owned by MGM and Entain plc, recorded a 35 percent year-over-year increase in net revenue to $1.35 billion for the six-month period. The business reported earnings of $109 million, compared with a $123 million loss in the prior year.

In the second quarter, revenue totaled $692 million, and earnings reached $86 million, an increase of $78 million from the same quarter in 2024. The iGaming segment generated $891 million in revenue during the half, up 28 percent year over year, while the online sports division brought in $422 million, reflecting a 61 percent increase. Average monthly active users reached 984,000 in the first half, a 6 percent rise from the previous year.

Following these results, MGM now projects full-year 2025 revenue from BetMGM of at least $2.7 billion and earnings of at least $150 million. The updated outlook compares to a prior forecast of $2.6 billion and $100 million, respectively. Growth in the period was attributed to increased player activity and engagement across both verticals.

In the second quarter, online sports betting handle increased by 25 percent to $3.4 billion. Net revenue margin improved by 130 basis points, reflecting changes in player management. MGM reported that BetMGM holds a 14 percent gross gaming revenue share in active markets, including 22 percent in iGaming.

Analyst Sentiment Mixed Following BetMGM Update

Susquehanna analyst Joseph Stauff maintained a Positive rating and raised the price target from $50 to $60.
Citizens JMP analyst Jordan Bender reiterated a Market Perform rating.

Which Analyst has the best track record to show on MGM?

Analyst Stephen Grambling (MORGAN STANLEY) currently has the highest performing score on MGM with 27/31 (87.1%) price target fulfillment ratio. His price targets carry an average of $0.07 (0.18%) potential upside. MGM Resorts International stock price reaches these price targets on average within 290 days.